Richard Conway
Tweet
MANDARA phase 3 RCT Benralizumab vs Mepolizumab in relapsing/refractory EGPA receiving SOC. Non-inferiority met. Abstr#L14 #ACR23 @RheumNow https://t.co/UnpF3RDHMa https://t.co/076SeynJx3


